JPWO2020188352A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020188352A5 JPWO2020188352A5 JP2021555469A JP2021555469A JPWO2020188352A5 JP WO2020188352 A5 JPWO2020188352 A5 JP WO2020188352A5 JP 2021555469 A JP2021555469 A JP 2021555469A JP 2021555469 A JP2021555469 A JP 2021555469A JP WO2020188352 A5 JPWO2020188352 A5 JP WO2020188352A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- medicament
- pharmaceutically acceptable
- acceptable salt
- diazaspiro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 51
- 150000003839 salts Chemical class 0.000 claims description 35
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 22
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 8
- ZNSPHKJFQDEABI-NZQKXSOJSA-N Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 Chemical compound Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 ZNSPHKJFQDEABI-NZQKXSOJSA-N 0.000 claims description 7
- TZSZZENYCISATO-WIOPSUGQSA-N rodatristat Chemical compound CCOC(=O)[C@@H]1CC2(CN1)CCN(CC2)c1cc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)nc(N)n1 TZSZZENYCISATO-WIOPSUGQSA-N 0.000 claims description 7
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 4
- 125000006005 fluoroethoxy group Chemical group 0.000 claims description 4
- 125000003652 trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims description 4
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 claims description 3
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000013078 crystal Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 33
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 31
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- YRCGAHTZOXPQPR-UHFFFAOYSA-N 2-ethylnonanoic acid Chemical compound CCCCCCCC(CC)C(O)=O YRCGAHTZOXPQPR-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819162P | 2019-03-15 | 2019-03-15 | |
| US62/819,162 | 2019-03-15 | ||
| PCT/IB2020/000177 WO2020188352A1 (en) | 2019-03-15 | 2020-03-13 | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022525202A JP2022525202A (ja) | 2022-05-11 |
| JP2022525202A5 JP2022525202A5 (https=) | 2023-02-13 |
| JPWO2020188352A5 true JPWO2020188352A5 (https=) | 2023-02-13 |
Family
ID=71092560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021555469A Pending JP2022525202A (ja) | 2019-03-15 | 2020-03-13 | 肺動脈性肺高血圧症および各種疾患に伴う肺動脈性肺高血圧症の治療法と１日あたりの投薬量 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11576915B2 (https=) |
| EP (1) | EP3938043A1 (https=) |
| JP (1) | JP2022525202A (https=) |
| KR (1) | KR20210139293A (https=) |
| CN (1) | CN113784717A (https=) |
| AU (1) | AU2020244278A1 (https=) |
| CA (1) | CA3133589A1 (https=) |
| MX (1) | MX2021011224A (https=) |
| WO (1) | WO2020188352A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022507533A (ja) * | 2018-11-16 | 2022-01-18 | アルタバント・サイエンシズ・ゲーエムベーハー | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 |
| US11607413B2 (en) * | 2019-01-30 | 2023-03-21 | Altavant Sciences Gmbh | Dosage regime and method for treating pulmonary arterial hypertension |
| US11576915B2 (en) | 2019-03-15 | 2023-02-14 | Altavant Sciences Gmbh | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
| WO2023062595A1 (en) * | 2021-10-14 | 2023-04-20 | Altavant Sciences Gmbh | Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101815534A (zh) * | 2007-07-11 | 2010-08-25 | 莱西肯医药有限公司 | 用于治疗肺动脉高压以及相关疾病和病症的方法和组合物 |
| UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| US9399741B2 (en) | 2013-10-09 | 2016-07-26 | Uop Llc | Methods and apparatuses for desulfurizing hydrocarbon streams |
| KR20210102887A (ko) * | 2018-11-14 | 2021-08-20 | 알타반트 사이언시스 게엠베하 | 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제 |
| JP2022507533A (ja) * | 2018-11-16 | 2022-01-18 | アルタバント・サイエンシズ・ゲーエムベーハー | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 |
| US20200188399A1 (en) | 2018-12-17 | 2020-06-18 | Altavant Sciences Gmbh | Method for treating interstitial lung disease |
| WO2020128608A1 (en) * | 2018-12-17 | 2020-06-25 | Altavant Sciences Gmbh | Compound for use in a method for treating sarcoidosis-associated pulmonary hypertension |
| US11607413B2 (en) | 2019-01-30 | 2023-03-21 | Altavant Sciences Gmbh | Dosage regime and method for treating pulmonary arterial hypertension |
| US11576915B2 (en) | 2019-03-15 | 2023-02-14 | Altavant Sciences Gmbh | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
-
2020
- 2020-03-13 US US16/818,236 patent/US11576915B2/en active Active
- 2020-03-13 AU AU2020244278A patent/AU2020244278A1/en not_active Abandoned
- 2020-03-13 CA CA3133589A patent/CA3133589A1/en active Pending
- 2020-03-13 CN CN202080033296.0A patent/CN113784717A/zh active Pending
- 2020-03-13 JP JP2021555469A patent/JP2022525202A/ja active Pending
- 2020-03-13 EP EP20732658.8A patent/EP3938043A1/en not_active Withdrawn
- 2020-03-13 MX MX2021011224A patent/MX2021011224A/es unknown
- 2020-03-13 WO PCT/IB2020/000177 patent/WO2020188352A1/en not_active Ceased
- 2020-03-13 KR KR1020217031156A patent/KR20210139293A/ko not_active Abandoned
-
2023
- 2023-01-04 US US18/149,992 patent/US20240024316A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6615755B2 (ja) | インフルエンザウイルスの複製の阻害剤 | |
| US20140066466A1 (en) | Necroptosis Inhibitors and Methods of Use Therefor | |
| TWI737861B (zh) | N-[5-(胺基磺醯基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙醯胺游離鹼半水合物、製造方法及其用途 | |
| US20190233470A1 (en) | Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis | |
| CN102389423A (zh) | 一种含有布洛芬钠盐的药用组合物 | |
| US10239848B2 (en) | Cyclohexenyl compounds, compositions comprising them and uses thereof | |
| JP6614741B2 (ja) | Ｐｉ３ｋを阻害する新規キナゾリノン誘導体とそれを含む医薬組成物 | |
| TW201737943A (zh) | 使用fasn抑制劑之方法 | |
| US20150238456A1 (en) | Methods and compositions for administration of oxybutynin | |
| CN113242736A (zh) | 一种治疗肺动脉高压和相关性肺动脉高压的方法 | |
| JP3832229B2 (ja) | フェニルエテンスルホンアミド誘導体含有医薬 | |
| EP2144887A1 (en) | Dosages and methods for the treatment of cancer | |
| AU2008259864C1 (en) | Methods and compositions for administration of Oxybutynin | |
| CN113784717A (zh) | 一种治疗肺动脉高压和相关性肺动脉高压的方法以及每日给药 | |
| CN107137417B (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| JP2018515527A (ja) | インフルエンザウイルスの複製の阻害剤 | |
| CN114650827A (zh) | 烟酰胺单核苷酸(nmn)用于预防和/或治疗类风湿性关节炎的用途和相应的组合物 | |
| JPWO2020188352A5 (https=) | ||
| CN113876775B (zh) | 一种青藤碱或其药物可接受的盐作为治疗动脉性肺动脉高压药物的用途 | |
| TWI411435B (zh) | ４－環丙基甲氧基－ｎ－（３，５－二氯－１－氧離子基吡啶－４－基）－５－（甲氧基）吡啶－２－甲醯胺於治療脊髓創傷之用途 | |
| JPWO2020099926A5 (https=) | ||
| CN100372533C (zh) | 腹泻为主大肠激惹综合征的治疗制剂 | |
| AU2013368298B2 (en) | Methods and compositions for administration of oxybutynin | |
| JP2010536827A (ja) | ある種の炎症性障害の治療に有用なカルボニルアミノ誘導体 | |
| JPWO2020157577A5 (https=) |